EMVision secures $3.8 million R&D rebate and overseas funding approval
EMVision Medical Devices (ASX: EMV) has received a $3.8 million R&D tax refund relating to eligible research and development activities undertaken in the financial year ended 30 June 2025. The EMVision $3.8 million R&D rebate announcement also confirms AusIndustry has approved the company’s Advance Overseas Finding application, covering eligible overseas expenditure associated with the emu™ pivotal (validation) trial and related market access activities.
The overseas finding approval enables EMVision to access the Australian Government’s cash R&D tax rebate at the current rate of 43.5% on eligible overseas R&D expenditure. This approval spans three financial years: FY25, FY26, and FY27. Together, the immediate cash injection and multi-year rebate eligibility strengthen EMVision’s funding position as it advances its emu™ pivotal (validation) trial and associated market access initiatives.
When big ASX news breaks, our subscribers know first
What is the R&D tax incentive and why does it matter for medtech investors?
Australia’s R&D Tax Incentive program provides a refundable tax offset to eligible companies, with the current cash R&D tax rebate rate at 43.5%. This government program effectively returns cash to companies undertaking qualifying research and development activities, reducing the net cost of innovation.
Advance Overseas Findings allow companies to claim rebates on qualifying international R&D expenditure, which would otherwise be ineligible. For EMVision, this includes US-based CRO and hospital site costs, as well as supporting administration, professional advisory and regulatory expenses associated with the emu™ pivotal (validation) trial and related market access activities.
How the funding supports the emu™ pivotal (validation) trial
The emu™ device is EMVision’s portable neurodiagnostic technology targeting stroke diagnosis at point-of-care. The pivotal (validation) trial represents the regulatory pathway toward commercialisation, with the Advance Overseas Finding now covering:
- US-based CRO costs
- Hospital site costs
- Administration and professional advisory expenses
- Regulatory expenses
Securing rebate eligibility on overseas trial costs reduces the effective cost of EMVision’s most capital-intensive development phase. The company’s vision is to help transform and improve the timely diagnosis and treatment of stroke and other time-sensitive medical emergencies at point-of-care using portable, non-invasive technology.
Funding position and next steps
The $3.8 million cash injection plus multi-year overseas rebate approval strengthens EMVision’s funding position. This supports both the emu™ pivotal (validation) trial and associated market access initiatives as the company advances these core programs.
The combined funding mechanisms provide EMVision with improved financial flexibility as it progresses its validation trial and related market access activities across the 2025, 2026 and 2027 financial years.
The next major ASX story will hit our subscribers first
About EMVision’s technology
EMVision Medical Devices is an Australian medical device company developing a novel approach to looking inside the human body. The company’s product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices. EMVision has offices in Sydney and Brisbane, focusing on technology that could help transform and improve the timely diagnosis and treatment of stroke and other time-sensitive medical emergencies at point-of-care.
Want the Next MedTech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts the moment market-moving announcements break across the healthcare and biotech sectors.